BioInfra Co.,Ltd.

As of June 30, 2026, BioInfra Co.,Ltd. carries a market capitalization of 11.19B, placing it among publicly traded companies globally. Its enterprise value stands at 17.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, BioInfra Co.,Ltd. has 4.86M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.44, and the price-to-book ratio stands at 0.89.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 17.89B versus a market cap of 11.19B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioInfra Co.,Ltd. maintains a current ratio of 0.58, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, BioInfra Co.,Ltd. posted a negative return on equity (ROE) of -47.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -22.87, reflecting losses generated across the asset base. The company generates approximately 184.67M in revenue per employee across its workforce of 138.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, BioInfra Co.,Ltd. recorded 1.05B in income tax expense. The company reported a pretax loss of -7.23B and -8.29B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, BioInfra Co.,Ltd.'s stock has declined approximately 63.82% over the past 52 weeks. The 50-day moving average sits at 1,398.24, while the 200-day moving average is 3,082.57.

Over the twelve months ended June 30, 2026, BioInfra Co.,Ltd. generated 25.62B in revenue and converted that into -8.29B in net income, yielding earnings per share of -1,688.07. EBITDA reached -1.74B, while operating income came in at -5.28B.

As of June 30, 2026, BioInfra Co.,Ltd. holds 7.04B in cash and equivalents against 13.74B in total debt, resulting in a net debt position of 9.87B. Total book value stands at 12.60B, with working capital of -8.77B providing operational flexibility.

BioInfra Co.,Ltd. produced -1.35B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.35B in capital expenditures, free cash flow totaled -2.70B - equivalent to -550.86 per share.

Over the twelve months ended June 30, 2026, BioInfra Co.,Ltd. posted a gross margin of 25.58, reflecting its pricing power and cost economics. The operating margin of -20.61 and net profit margin of -32.34 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, BioInfra Co.,Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -23.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.52, meaning BioInfra Co.,Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, BioInfra Co.,Ltd. has an Altman Z-Score of 0.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.